Advertisement
Screener

Standard BioTools Inc. (LAB) Inventory, LIFO Reserve, Period Charge

2.8 / 5 stars · 68/120 Roast Me

Standard BioTools Inc. Inventory, LIFO Reserve, Period Charge

Standard BioTools Inc. (LAB) reported Inventory, LIFO Reserve, Period Charge of $1.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:InventoryLIFOReservePeriodCharge · last filed 2026-08-05

  • Standard BioTools Inc. inventory, lifo reserve, period charge for the quarter ending 2026-06-30 was $1.07M, a 97.06% increase year-over-year.
  • Standard BioTools Inc. inventory, lifo reserve, period charge for the quarter ending 2026-03-31 was $696.00K, a 14.60% decline year-over-year.
  • Standard BioTools Inc. inventory, lifo reserve, period charge for the quarter ending 2025-12-31 was $1.49M, a 180.11% increase year-over-year.
  • Standard BioTools Inc. inventory, lifo reserve, period charge for the quarter ending 2025-09-30 was $615.00K, a 515.00% increase year-over-year.
  • Standard BioTools Inc. inventory, lifo reserve, period charge for fiscal 2025 was $3.47M, a 37.40% increase from fiscal 2024.
  • Standard BioTools Inc. inventory, lifo reserve, period charge for fiscal 2024 was $2.52M, a 68.72% increase from fiscal 2023.
  • Standard BioTools Inc. inventory, lifo reserve, period charge for fiscal 2023 was $1.50M, a 81.00% decline from fiscal 2022.
  • Standard BioTools Inc. inventory, lifo reserve, period charge for fiscal 2022 was $7.87M, a 243.39% increase from fiscal 2021.
Period endInventory, LIFO Reserve, Period Charge 3 monthInventory, LIFO Reserve, Period Charge 6 monthInventory, LIFO Reserve, Period Charge 9 monthInventory, LIFO Reserve, Period Charge 12 monthInventory, LIFO Reserve, Period Charge 12 month as first filed
2026-06-30$1.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$1.77M
10-Q · filed 2026-08-05
$3.26M
derived: sum of 3 quarters · filed 2026-08-05
$3.88M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$696.00K
10-Q · filed 2026-05-06
$2.19M
derived: sum of 2 quarters · filed 2026-05-06
$2.80M
derived: sum of 3 quarters · filed 2026-05-06
$3.35M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$1.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$2.11M
derived: sum of 2 quarters · filed 2026-03-16
$2.65M
derived: sum of 3 quarters · filed 2026-08-05
$3.47M
10-K · filed 2026-03-16
2025-09-30$615.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$1.16M
derived: sum of 2 quarters · filed 2026-08-05
$1.98M
10-Q · filed 2025-11-04
$2.51M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$545.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$1.36M
10-Q · filed 2026-08-05
$1.89M
derived: sum of 3 quarters · filed 2026-08-05
$1.99M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$815.00K
10-Q · filed 2026-05-06
$1.35M
derived: sum of 2 quarters · filed 2026-05-06
$1.45M
derived: sum of 3 quarters · filed 2026-05-06
$2.65M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$533.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$633.00K
derived: sum of 2 quarters · filed 2026-03-16
$1.83M
derived: sum of 3 quarters · filed 2026-03-16
$2.52M
10-K · filed 2026-03-16
2024-09-30$100.00K
10-Q · filed 2024-11-06
$1.30M
derived: sum of 2 quarters · filed 2024-11-06
$1.99M
10-Q · filed 2025-11-04
$2.49M
derived: sum of 4 quarters · filed 2026-03-16
2024-06-30$1.20M
10-Q · filed 2024-08-06
$1.87M
10-Q · filed 2025-08-15
$2.39M
derived: sum of 3 quarters · filed 2026-03-16
$2.79M
derived: sum of 4 quarters · filed 2026-03-16
2024-03-31$655.00K
10-Q · filed 2025-05-06
$1.19M
derived: sum of 2 quarters · filed 2026-03-16
$1.59M
derived: sum of 3 quarters · filed 2026-03-16
$1.79M
derived: sum of 4 quarters · filed 2026-03-16
2023-12-31$533.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
$933.00K
derived: sum of 2 quarters · filed 2026-03-16
$1.13M
derived: sum of 3 quarters · filed 2026-03-16
$1.50M
10-K · filed 2026-03-16
2023-09-30$400.00K
10-Q · filed 2024-11-06
$600.00K
derived: sum of 2 quarters · filed 2024-11-06
$963.00K
10-Q · filed 2024-11-06
$1.58M
derived: sum of 4 quarters · filed 2025-03-11
2023-06-30$200.00K
10-Q · filed 2024-08-06
$572.00K
10-Q · filed 2024-08-06
$1.19M
derived: sum of 3 quarters · filed 2025-03-11
$3.83M
derived: sum of 4 quarters · filed 2025-03-11
2023-03-31$350.00K
10-Q · filed 2024-05-09
$985.00K
derived: sum of 2 quarters · filed 2025-03-11
$3.63M
derived: sum of 3 quarters · filed 2025-03-11
$7.37M
derived: sum of 4 quarters · filed 2025-03-11
2022-12-31$635.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$3.28M
derived: sum of 2 quarters · filed 2025-03-11
$7.02M
derived: sum of 3 quarters · filed 2025-03-11
$7.87M
10-K · filed 2025-03-11
2022-09-30$2.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
$6.39M
derived: sum of 2 quarters · filed 2023-11-07
$7.24M
10-Q · filed 2023-11-07
$7.99M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$3.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$4.60M
10-Q · filed 2023-08-08
$5.35M
derived: sum of 3 quarters · filed 2023-08-08
$5.64M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31$851.00K
10-Q · filed 2023-05-09
$1.60M
derived: sum of 2 quarters · filed 2023-05-09
$1.90M
derived: sum of 3 quarters · filed 2023-05-09
$2.83M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$754.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
$1.04M
derived: sum of 2 quarters · filed 2023-03-14
$1.98M
derived: sum of 3 quarters · filed 2023-03-14
$2.29M
10-K · filed 2023-03-14
2021-09-30$291.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$1.22M
derived: sum of 2 quarters · filed 2022-11-09
$1.54M
10-Q · filed 2022-11-09
$2.47M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$933.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$1.25M
10-Q · filed 2022-08-09
$2.18M
derived: sum of 3 quarters · filed 2022-08-09
$2.56M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$315.00K
10-Q · filed 2022-05-09
$1.25M
derived: sum of 2 quarters · filed 2022-05-09
$1.62M
derived: sum of 3 quarters · filed 2022-05-09
$1.73M
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31$934.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$1.31M
derived: sum of 2 quarters · filed 2022-03-08
$1.42M
derived: sum of 3 quarters · filed 2022-03-08
$1.61M
10-K · filed 2022-03-08
2020-09-30$374.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$485.00K
derived: sum of 2 quarters · filed 2021-11-09
$680.00K
10-Q · filed 2021-11-09
$1.13M
derived: sum of 4 quarters · filed 2022-03-08
2020-06-30$111.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06
$306.00K
10-Q · filed 2021-08-06
$757.00K
derived: sum of 3 quarters · filed 2022-03-08
$1.56M
derived: sum of 4 quarters · filed 2022-03-08
2020-03-31$195.00K
10-Q · filed 2021-05-07
$646.00K
derived: sum of 2 quarters · filed 2022-03-08
$1.45M
derived: sum of 3 quarters · filed 2022-03-08
$1.87M
derived: sum of 4 quarters · filed 2022-03-08
2019-12-31$451.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$1.25M
derived: sum of 2 quarters · filed 2022-03-08
$1.67M
derived: sum of 3 quarters · filed 2022-03-08
$1.81M
10-K · filed 2022-03-08
$1.45M
10-K · filed 2020-02-27
2019-09-30$801.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$1.22M
derived: sum of 2 quarters · filed 2020-11-09
$1.36M
10-Q · filed 2020-11-09
2019-06-30$420.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$555.00K
10-Q · filed 2020-08-07
2019-03-31$135.00K
10-Q · filed 2020-05-11
2018-12-31$1.09M
10-K · filed 2021-02-25
$1.03M
10-K · filed 2020-02-27
2017-12-31$434.00K
10-K · filed 2020-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01